2006 Jan 23;580(2):613-9. Epub 2006 Jan 3.
Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition.
Nakajima Y1, Furuichi Y, Biswas KK, Hashiguchi T, Kawahara K, Yamaji K, Uchimura T, Izumi Y, Maruyama I.
- FEBS Lett. 2006 Mar 20;580(7):1909.
Anandamide (AEA) exhibits anti-inflammatory effects. However, its role in the periodontal field remains unknown. Here, we found that gingival crevicular fluid contained a detectable level of AEA. The cannabinoid receptors CB1 and CB2 were expressed by human gingival fibroblasts (HGFs), and markedly upregulated under pathological conditions. AEA significantly reduced the production of pro-inflammatory mediators (IL-6, IL-8 and MCP-1) induced by Porphyromonas gingivalis LPS in HGFs, and this effect was attenuated by AM251 and SR144528, selective antagonists of CB1 and CB2, respectively. Moreover, AEA completely blocked LPS-triggered NF-kappaB activation, implying that AEA may regulate hyperinflammatory reactions in periodontitis.
- [PubMed – indexed for MEDLINE]
- Arachidonic Acids/metabolism*
- Cannabinoid Receptor Modulators/metabolism*
- Cells, Cultured
- Fibroblasts/drug effects
- Gingival Crevicular Fluid/chemistry
- NF-kappa B/antagonists & inhibitors
- NF-kappa B/metabolism*
- Polyunsaturated Alkamides
- Receptor, Cannabinoid, CB1/genetics
- Receptor, Cannabinoid, CB1/metabolism
- Receptor, Cannabinoid, CB2/genetics
- Receptor, Cannabinoid, CB2/metabolism
- Signal Transduction/physiology*